

**ASX Announcement | 20 December 2022  
Vioneering Technologies (ASX:VTI)**

**Kathleen Miller Joins VTI as Independent Director**

**Atlanta, Georgia, USA Monday, 19 December 2022 (Sydney Tuesday, 20 December 2022):** US-based medical device company and producer of the NaturalVue® Multifocal 1 Day Contact Lenses, [Vioneering Technologies, Inc \(ASX:VTI\)](#) ('Vioneering', 'VTI' or 'the Company') today announced the appointment of Ms. Kathleen Miller as an independent non-executive director and chair of the Audit & Risk Committee along with the pending retirement of Ms. Jean Franchi from its Board of Directors.

Ms. Miller is an experienced public company board member and Audit Committee Chair with over 30 years of leading and advising boards of public and high-growth companies on finance, accounting, compensation, mergers & acquisitions, initial public offerings, governance, strategy and operations. Kathy currently serves as a Non-executive Director and Audit Committee Chair for Tecsyst (TO: TCS), a leading supply chain and complex distribution management system provider; Non-Executive Director, Audit Committee and Compensation Committee member for IOU Financial (TSXV:IOU), a fintech small business lender; Non-Executive Director, Audit Committee and Governance Committee member for Kaleyra (NYSE:KLR), an omnichannel business communications platform; and Audit Committee Chair for True Commerce, a private equity backed leader in EDI and multi-enterprise supply chain eCommerce and business networks.

Prior to her retirement, Kathy was CFO of Nitro Software, Inc. (ASX: NTO), a high growth SaaS-based workflow productivity company, where she contributed to 200% recurring revenue CAGR and 95% client retention. Through her CFO role and at the board level, she led the ASX IPO for this \$40M business. Previously, Kathy led dual roles as CFO and COO of nCourt LLC, a high-growth SaaS-based software and payment service provider with \$4B+ in processed funds, overseeing all operational and financial functions.

Ms. Miller earned a MS in the Study of Law, magna cum laude from Fordham University and a BS in Accounting, cum laude from Alfred University.

On behalf of the Board of Directors, Vioneering's Chairman, Dr. David J. Mazzo, said, "Ms. Miller brings a wealth of experience and expertise to VTI as an experienced independent board director and a Qualified Financial Expert. We welcome her to the VTI Board of Directors and believe her combination of deep financial expertise and success in leading businesses to strong revenue growth will be an asset to VTI."

In conjunction with Ms. Miller's appointment, Ms. Jean Franchi, VTI's current chair of the Audit and Risk Committee, will be stepping down from the Board of Directors to focus on other commitments following five years of service. Jean will remain a board director through 31 December 2022 to assure the smooth transition of her Audit and Risk Committee role to Ms. Miller.

Dr. Mazzo said, “On behalf of the Board and management, I thank Jean for her many years of service to VTI. Jean joined the Board in 2017 and helped guide the Company through the transition from private to public company. She has made significant contributions to the growth and accomplishments of VTI. We will miss her and wish her all the best in future endeavors.”

**Ends**

**This release was authorized by the COO and CFO, Brian Lane.**

**For more information, please contact:**

<b>Company</b>	<b>Investor and media relations</b>
Brian Lane COO and CFO, Visioneering Technologies, Inc. Email: <a href="mailto:blane@vtivision.com">blane@vtivision.com</a>	Haley Chartres H^CK Tel: +61 423 139 163 Email: <a href="mailto:haley@hck.digital">haley@hck.digital</a>

### **About Visioneering Technologies**

Visioneering Technologies Inc. (ASX:VTI) is an innovative eye care company committed to redefining vision. A pioneer in myopia management, VTI merges advanced engineering with a relentless drive to achieve superior results for patients and practitioners. VTI's flagship product is the NaturalVue® (etafilcon A) Multifocal 1-Day Contact Lens, an extended depth of focus lens that is one of the most significant innovations in the eye care industry in more than 20 years. For more information, please visit [www.vtivision.com](http://www.vtivision.com) or call +1 844-884-5367, ext. 104.

### **Foreign ownership restrictions**

VTI's CHES Depositary Interests (**CDIs**) are issued in reliance on the exemption from registration contained in Regulation S of the US Securities Act of 1933 (**Securities Act**) for offers that are made outside the US. Accordingly, the CDIs have not been, and will not be, registered under the Securities Act or the laws of any state or other jurisdiction in the US. As a result of relying on the Regulation S exemption, the CDIs are 'restricted securities' under Rule 144 of the Securities Act. This means that you are unable to sell the CDIs into the US or to a US person for the foreseeable future except in very limited circumstances after the expiration of a restricted period, unless the re-sale of the CDIs is registered under the Securities Act, or an exemption is available. To enforce the above transfer restrictions, all CDIs issued bear a 'FOR US' designation on the Australian Securities Exchange (**ASX**). This designation restricts any CDIs from being sold on ASX to US persons. However, you are still able to freely transfer your CDIs on ASX to any person other than a US person. In addition, hedging transactions with regard to the CDIs may only be conducted in accordance with the Securities Act.

### **Forward-Looking Statements**

This announcement contains or may contain forward-looking statements that are based on management's beliefs, assumptions and expectations and on information currently available to management.

All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements. These include, without limitation, U.S. commercial market acceptance and U.S. sales of our product, as well as our expectations with respect to our ability to develop and commercialize new products.

Given the current uncertainties regarding the on-going impact of COVID-19 on the trading conditions impacting VTI, the financial markets and the health services world-wide, there can be no assurance that future developments will be in accordance with VTI's expectations or that the effect of future developments on VTI will be those anticipated.

Management believes that these forward-looking statements are reasonable when made. You should not place undue reliance on forward-looking statements because they speak only as of the date when made. VTI does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. VTI may not actually achieve the plans, projections or expectations disclosed in forward-looking statements. Actual results, developments or events could differ materially from those disclosed in the forward-looking statements.

VTI-IR-ASX72